Features of the course and diagnosis of chronic sarcoidosis
https://doi.org/10.18705/2311-4495-2024-11-1-6-18
EDN: AFQHOM
Abstract
Sarcoidosis is a systemic inflammatory disease of unknown etiology with a wide range of clinical manifestations. The annual incidence ranges from 1 to 15 per 100,000 population. Due to the lack of specific clinical features, the diagnosis of this disease is still challenging. The significant variability in clinical presentations and target organs, as well as concomitant diseases, greatly complicate the diagnostic search and make sarcoidosis a diagnosis of exclusion. This article discusses a clinical case of a patient with generalized chronic sarcoidosis and provides a review and analysis of the current literature on this issue. At the moment, there is no biomarker or combination of biomarkers that would reliably predict the development and spread of the pathological process.
About the Authors
E. E. Berg
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Elizaveta E. Berg, 6-th year student
medical faculty
197341; ul. Akkuratova d. 2; Saint Petersburg
tel.: +79658149803
I. V. Kudryavtsev
Scientific Research Institute of Experimental Medicine
Russian Federation
Russian Federation
Igor V. Kudryavtsev, PhD., Head of laboratory
Institute of Experimental Medicine; laboratory of cellular immunology
Saint Petersburg
D. A. Kudlay
Sechenov First Moscow State Medical University; National Research Center — Institute of Immunology Federal Medical-
Biological Agency; Lomonosov Moscow State University
Russian Federation
Russian Federation
Dmitry A. Kudlay DMedSci, MD, corresponding member of the Russian Academy of Sciences, Professor, Professor of the Department, Leading Researcher
Institute of Pharmacy; Department of Pharmacology; Faculty of Fundamental Medicine; Department of Pharmacognosy
and Industrial Pharmacy; NRC Institute of Immunology; Laboratory of Personalized Medicine and Molecular Immunology
115552; Kashirskoye highway; Moscow
Scopus AuthorID: https://www.scopus.com/authid/detail.uri?authorId=57225772840
tel.: +79857610237
A. A. Starshinova
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Anna A. Starshinova, DMedSci, MD, pulmonologist,
Head of the department
research department
197341; Akkuratova str., 2; Saint Petersburg
email: starshinova_777@mail.ru
tel.: +79052043861
References
1. Визель А.А., Визель И.Ю., Амиров Н.Б. Эпидемиология саркоидоза в Российской Федерации. Вестник современной клинической медицины. 2017; 10(5):66–73 DOI: 10.20969/VSKM.2017.10(5).66-73.
2. Inaoka PT, Shono M, Kamada M, Espinoza JL. Host-microbe interactions in the pathogenesis and clinical course of sarcoidosis. J Biomed Sci. 2019; 26(1):45. DOI: 10.1186/s12929-019-0537-6.
3. Schupp JC, Freitag-Wolf S, Bargagli E, et al. Phenotypes of organ involvement in sarcoidosis. Eur Respir J. 2018; 51(1):1700991. DOI: 10.1183/13993003.00991-2017.
4. Newman LS, Rose CS, Bresnitz EA, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004;170(12):1324–30. DOI: 10.1164/rccm.200402-249OC.
5. Starshinova A, Zinchenko Y, Malkova A, et al. Sarcoidosis and Autoimmune Inflammatory Syndrome Induced by Adjuvants. Life (Basel). 2023;13(4):1047. DOI: 10.3390/life13041047.
6. Polverino F, Balestro E, Spagnolo P. Clinical Presentations, Pathogenesis, and Therapy of Sarcoidosis: State of the Art. J Clin Med. 2020; 9(8):2363. DOI: 10.3390/jcm9082363.
7. Старшинова А.А., Малкова А.М., Зинченко Ю.С. и др. Аутоиммунная составляющая в этиологии саркоидоза. Туберкулез и болезни легких. 2020; 98(5):54–62. DOI: 10.21292/2075-1230-2020-98-5-54-62.
8. Gavrilova N, Zinchenko Y, Belyaeva E, et al. Small Fiber Neuropathy in Sarcoidosis. Pathophysiology. 2021; 28(4):544–550. DOI: 10.3390/pathophysiology28040035.
9. Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020; 201(8):e26–e51. DOI: 10.1164/rccm.202002-0251ST.
10. Akao K, Minezawa T, Yamamoto N, et al. Flow cytometric analysis of lymphocyte profiles in mediastinal lymphadenopathy of sarcoidosis. PLoS One. 2018; 13(11):e0206972. DOI: 10.1371/journal.pone.0206972.
11. Obi ON, Saketkoo LA, Russell AM, et al. Sarcoidosis: Updates on therapeutic drug trials and novel treatment approaches. Front Med (Lausanne). 2022; 9:991783. DOI: 10.3389/fmed.2022.991783.
12. Jeny F, Bernaudin JF, Cohen Aubart F, et al. Diagnosis issues in sarcoidosis. Respir Med Res. 2020; 77:37–45. DOI: 10.1016/j.resmer.2019.09.002.
13. Kraaijvanger R, Janssen Bonás M, Vorselaars ADM, et al. Biomarkers in the Diagnosis and Prognosis of Sarcoidosis: Current Use and Future Prospects. Front Immunol. 2020; 11:1443. DOI: 10.3389/fimmu.2020.01443.
14. Ramos-Casals M, Retamozo S, Sisó-Almirall A, et al. Clinically-useful serum biomarkers for diagnosis and prognosis of sarcoidosis. Expert Rev Clin Immunol. 2019; 15(4):391–405. DOI: 10.1080/1744666X.2019.1568240.
15. Zhou Y, Chen X, Zhao M, et al. SACE and IL-2R as serum biomarkers for evaluation of multi-organ involvement and prognosis of sarcoidosis. Respir Res. 2023; 24(1):219. DOI: 10.1186/s12931-023-02524-0.
16. Levy A, Hamzeh N, Maier LA. Is it time to scrap Scadding and adopt computed tomography for initial evaluation of sarcoidosis? F1000Res. 2018; 7:F1000 Faculty Rev-600. DOI: 10.12688/f1000research.11068.1.
17. Sève P, Pacheco Y, Durupt F, et al. Sarcoidosis: A Clinical Overview from Symptoms to Diagnosis. Cells. 2021; 10(4):766. DOI: 10.3390/cells10040766.
18. Ramirez R, Trivieri M, Fayad ZA, et al. Advanced Imaging in Cardiac Sarcoidosis. J Nucl Med. 2019; 60(7):892–898. DOI: 10.2967/jnumed.119.228130.
19. Al Hayja MA, Vinjamuri S. Cardiac sarcoidosis: the role of cardiac MRI and 18F-FDG-PET/CT in the diagnosis and treatment follow-up. Br J Cardiol. 2023; 30(1):7. DOI: 10.5837/bjc.2023.007.
20. Strambu IR. Challenges of cardiac sarcoidosis. Front Med (Lausanne). 2023; 10:999066. DOI: 10.3389/fmed.2023.999066.
21. Vender RJ, Aldahham H, Gupta R. The role of PET in the management of sarcoidosis. Curr Opin Pulm Med. 2022; 28(5):485–491. DOI: 10.1097/MCP.0000000000000892.
22. Kim J, Dwivedi G, Boughton BA, et al. Advances in cellular and tissue-based imaging techniques for sarcoid granulomas. American Journal of Physiology-Cell Physiology. 2024; 326(1):C10–C26. DOI: 10.1152/ajpcell.00507.2023.
23. Tana C, Donatiello I, Caputo A, et al. Clinical Features, Histopathology and Differential Diagnosis of Sarcoidosis. Cells. 2021 Dec 26;11(1):59. DOI: 10.3390/cells11010059.
24. Перенести в английский вариант
25. Visel AA, Visel IYu, Amirov NB. Epidemiology of sarcoidosis in the Russian Federation. The Bulletin of Contemporary Clinical Medicine. 2017; 10 (5): 66–73. In Russian DOI: 10.20969/VSKM.2017.10(5).66-73.
26. Inaoka PT, Shono M, Kamada M, Espinoza JL. Host-microbe interactions in the pathogenesis and clinical course of sarcoidosis. J Biomed Sci. 2019; 26(1):45. DOI: 10.1186/s12929-019-0537-6.
27. Schupp JC, Freitag-Wolf S, Bargagli E, et al. Phenotypes of organ involvement in sarcoidosis. Eur Respir J. 2018; 51(1):1700991. DOI: 10.1183/13993003.00991-2017.
28. Newman LS, Rose CS, Bresnitz EA, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004;170(12):1324–30. DOI: 10.1164/rccm.200402-249OC.
29. Starshinova A, Zinchenko Y, Malkova A, et al. Sarcoidosis and Autoimmune Inflammatory Syndrome Induced by Adjuvants. Life (Basel). 2023;13(4):1047. DOI: 10.3390/life13041047.
30. Polverino F, Balestro E, Spagnolo P. Clinical Presentations, Pathogenesis, and Therapy of Sarcoidosis: State of the Art. J Clin Med. 2020; 9(8):2363. DOI: 10.3390/jcm9082363.
31. Starshinova AA, Malkova АM, Zinchenko YuS, et al. Autoimmune component in the etiology of sarcoidosis. uberculosis and Lung Diseases, 2020, Vol. 98, No. 5, P. 54–62. In Russian DOI: 10.21292/2075-1230-2020-98-5-54-62.
32. Gavrilova N, Zinchenko Y, Belyaeva E, et al. Small Fiber Neuropathy in Sarcoidosis. Pathophysiology. 2021; 28(4):544–550. DOI: 10.3390/pathophysiology28040035.
33. Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020; 201(8):e26–e51. DOI: 10.1164/rccm.202002-0251ST.
34. Akao K, Minezawa T, Yamamoto N, et al. Flow cytometric analysis of lymphocyte profiles in mediastinal lymphadenopathy of sarcoidosis. PLoS One. 2018; 13(11):e0206972. DOI: 10.1371/journal.pone.0206972.
35. Obi ON, Saketkoo LA, Russell AM, et al. Sarcoidosis: Updates on therapeutic drug trials and novel treatment approaches. Front Med (Lausanne). 2022; 9:991783. DOI: 10.3389/fmed.2022.991783.
36. Jeny F, Bernaudin JF, Cohen Aubart F, et al. Diagnosis issues in sarcoidosis. Respir Med Res. 2020; 77:37–45. DOI: 10.1016/j.resmer.2019.09.002.
37. Kraaijvanger R, Janssen Bonás M, Vorselaars ADM, et al. Biomarkers in the Diagnosis and Prognosis of Sarcoidosis: Current Use and Future Prospects. Front Immunol. 2020; 11:1443. DOI: 10.3389/fimmu.2020.01443.
38. Ramos-Casals M, Retamozo S, Sisó-Almirall A, et al. Clinically-useful serum biomarkers for diagnosis and prognosis of sarcoidosis. Expert Rev Clin Immunol. 2019; 15(4):391–405. DOI: 10.1080/1744666X.2019.1568240.
39. Zhou Y, Chen X, Zhao M, et al. SACE and IL-2R as serum biomarkers for evaluation of multi-organ involvement and prognosis of sarcoidosis. Respir Res. 2023; 24(1):219. DOI: 10.1186/s12931-023-02524-0.
40. Levy A, Hamzeh N, Maier LA. Is it time to scrap Scadding and adopt computed tomography for initial evaluation of sarcoidosis? F1000Res. 2018; 7:F1000 Faculty Rev-600. DOI: 10.12688/f1000research.11068.1.
41. Sève P, Pacheco Y, Durupt F, et al. Sarcoidosis: A Clinical Overview from Symptoms to Diagnosis. Cells. 2021; 10(4):766. DOI: 10.3390/cells10040766.
42. Ramirez R, Trivieri M, Fayad ZA, et al. Advanced Imaging in Cardiac Sarcoidosis. J Nucl Med. 2019; 60(7):892–898. DOI: 10.2967/jnumed.119.228130.
43. Al Hayja MA, Vinjamuri S. Cardiac sarcoidosis: the role of cardiac MRI and 18F-FDG-PET/CT in the diagnosis and treatment follow-up. Br J Cardiol. 2023; 30(1):7. DOI: 10.5837/bjc.2023.007.
44. Strambu IR. Challenges of cardiac sarcoidosis. Front Med (Lausanne). 2023; 10:999066. DOI: 10.3389/fmed.2023.999066.
45. Vender RJ, Aldahham H, Gupta R. The role of PET in the management of sarcoidosis. Curr Opin Pulm Med. 2022; 28(5):485–491. DOI: 10.1097/MCP.0000000000000892.
46. Kim J, Dwivedi G, Boughton BA, et al. Advances in cellular and tissue-based imaging techniques for sarcoid granulomas. American Journal of Physiology-Cell Physiology. 2024; 326(1):C10–C26. DOI: 10.1152/ajpcell.00507.2023.
47. Tana C, Donatiello I, Caputo A, et al. Clinical Features, Histopathology and Differential Diagnosis of Sarcoidosis. Cells. 2021 Dec 26;11(1):59. DOI: 10.3390/cells11010059.
Review
For citations:
Berg E.E., Kudryavtsev I.V., Kudlay D.A., Starshinova A.A. Features of the course and diagnosis of chronic sarcoidosis. Translational Medicine. 2024;11(1):6-18. (In Russ.) https://doi.org/10.18705/2311-4495-2024-11-1-6-18. EDN: AFQHOM
Views:
589
Email this article 